Thalia Therapeutics Plc — New Patent Granted for miRisten in China

Thalia secures Chinese patent for miRisten, but clinical data remains years away.

What the company is saying

Thalia Therapeutics plc announces the granting and issue of a Chinese patent for miRisten (THAT-001), its lead clinical-stage programme targeting acute myeloid leukaemia (AML). The company frames this as a major step in strengthening its intellectual property position in China, a market it describes as highly valuable. The announcement highlights that miRisten is already protected by patents in the US, UK, Germany, France, Japan, and EPO countries, and that the underlying IP was exclusively licensed from City of Hope to Sanmirna Therapeutics Inc., which Thalia acquired in July 2026. Dr David Solomon, CEO, is quoted emphasizing the importance of this patent in supporting the clinical programme and the focus on upcoming clinical milestones. The company stresses the unmet medical need in AML, especially in China, and references large patient population estimates to underscore potential market opportunity. Thalia reiterates that its immediate focus is on completing the ongoing Phase 1 trial in the United States, with top-line data targeted for the first half of 2027. The tone is confident and positions the patent as a strategic win, but there is no mention of commercial agreements, revenue, or near-term product launches.

What the data suggests

The only realised milestone is the grant of a Chinese patent for miRisten, extending protection to a market with an estimated 30,400 new AML diagnoses in 2026. The company cites a 2019 population-based study estimating 43,275 new acute leukaemia cases across all subtypes in China, but does not provide a breakdown of how many would be eligible for miRisten, which is focused on relapsed or refractory AML. The Phase 1 clinical trial for miRisten is ongoing in the United States, with results not expected until the first half of 2027. No interim clinical data, commercial partnerships, or financial figures are disclosed. The announcement provides no information on current revenue, cash position, or funding status. The evidence supports incremental progress on IP protection, but there is no direct link to near-term commercialisation or financial impact. The company’s estimate of 30,400 AML cases is not independently sourced within the release, and the larger 43,275 figure is drawn from a published study but covers all acute leukaemia subtypes.

Analysis

The announcement is positive in tone, highlighting the grant of a Chinese patent for miRisten and the ongoing Phase 1 clinical trial. The core realised progress is the patent grant and the continued accrual of patients in the Phase 1 trial, both of which are concrete milestones for a clinical-stage biotech. However, the main clinical catalyst—top-line Phase 1 data—is not expected until the first half of 2027, making the execution distance long-term. The acquisition of Sanmirna Therapeutics Inc. in July 2026 signals a likely significant capital outlay, but there is no disclosure of revenue, profit, or cash flow, and no immediate earnings impact is claimed. The announcement references large market opportunity figures (e.g., 30,400 new AML cases in China) to frame potential, but these are not tied to any near-term commercial or financial outcomes. The language is generally proportionate for a biotech at this stage, but the emphasis on market size and future data readouts introduces moderate narrative inflation relative to the actual, incremental progress disclosed.

Risk flags

• ●Clinical development risk is high, as miRisten is still in Phase 1 trials with no efficacy or safety data disclosed. Failure to demonstrate positive results could halt progress regardless of patent coverage.
• ●Commercialisation risk is substantial, since the patent grant does not guarantee regulatory approval or market uptake in China. The addressable patient population for relapsed or refractory AML is a subset of the 30,400 new AML cases, and no market access or reimbursement pathways are described.
• ●Execution risk exists around the integration of Sanmirna Therapeutics Inc., acquired in July 2026, and the ability to leverage City of Hope’s IP and financial interest into tangible clinical or commercial results.
• ●Financial disclosure risk is present, as the company provides no information on cash reserves, funding runway, or partnership support, leaving investors unable to assess sustainability through the long clinical timeline.

Bottom line

Thalia’s new Chinese patent for miRisten strengthens its intellectual property position in a major market, but the company remains at an early clinical stage with no efficacy data and no disclosed commercial partnerships. The cited market size figures—30,400 new AML cases in China in 2026 and 43,275 acute leukaemia cases in 2019—highlight potential, but only a fraction of these patients may be eligible for miRisten. The critical clinical milestone, Phase 1 top-line data, is not expected until the first half of 2027, so any revenue or licensing upside is distant and contingent on positive results. The absence of financial disclosures or interim catalysts leaves a long execution gap. Investors should focus on the delivery of clinical data and any future updates on partnerships, funding, or regulatory progress. The main takeaway is that this is a strategic but early-stage step, with real value dependent on future clinical outcomes.

Announcement summary

(AIM: THAT) Thalia Therapeutics plc announced the granting and issue of a Chinese patent for miRisten (THAT-001), its lead clinical-stage programme for acute myeloid leukaemia (AML). The patent covers the use of miRisten in China and extends the intellectual property protection already granted in the US, UK, Germany, France, Japan, and EPO countries. The intellectual property was exclusively licensed from City of Hope to Sanmirna Therapeutics Inc., which Thalia acquired in July 2026. miRisten is an anti-microRNA-126 therapeutic being developed for patients with AML, particularly those with relapsed or refractory disease. The drug is currently being evaluated in a Phase 1 dose-escalation clinical trial in patients with relapsed or refractory AML at City of Hope in the United States. Thalia is targeting top-line data from this trial in the first half of 2027. Dr David Solomon, Chief Executive Officer of Thalia, stated that the new patent strengthens the intellectual property supporting the lead clinical programme and is an important part of its development. The Phase 1 trial continues to accrue patients, and results are anticipated in H1 2027. Thalia estimates that approximately 30,400 people will be newly diagnosed with AML in China in 2026. A population-based study published in The Lancet Haematology in 2025 estimated 43,275 new cases of acute leukaemia across all subtypes in China in 2019. City of Hope has a financial interest in Thalia Therapeutics plc, which owns Sanmirna Therapeutics Inc.

Disagree with this article?